Department of Anaesthesiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Anesthesiology. 2010 Jun;112(6):1374-81. doi: 10.1097/ALN.0b013e3181d6929d.
This three-staged study estimated the volume and concentration of interscalene ropivacaine that would prevent recovery room pain after shoulder surgery under general anesthesia.
Stages 1/2: Interscalene catheter administration of ropivacaine was by a 10% incremental up-down sequential manner depending on the presence of recovery room pain in the previous patient. Stage 1: Ropivacaine (0.5% volume) was varied from 30 ml. Stage 2: Ropivacaine (20 ml, the ED(volume)95 estimate from stage 1) concentration was varied from 0.45%. Stage 3: Subjects were randomly assigned to receive 30 ml of ropivacaine, 0.5% ("conventional dose"), or 20 ml of ropivacaine, 0.375% (the estimated ED(volume+concentration)95 from stages 1/2). A postoperative elastomeric infusion of 0.2% ropivacaine (2 ml/h) was administered. Grip strength was measured in the recovery room and time to first pain at 24 h.
Stage 1 (n = 34): Ropivacaine 0.5% ED(volume)50/ED(volume)95 (95% CI) estimates were 2.7/20.5 ml (2.4-9.5/17.3-25.8). Stage 2 (n = 29): Ropivacaine 20 ml ED(concentration)50/ED(concentration)95 (95% CI) estimates were 0.15/0.34% (0.13-0.30/0.29-0.43). The ED(dose)50 was similar for stages 1/2 (13.5 vs. 30 mg), but the ED(dose)95 was higher for stage 1 (102.5 vs. 68 mg). Stage 3 (n = 40): Satisfaction (0-10) was modestly higher for the new/lower dose (median [interquartile range] = 10 [10-10] versus 9 [8-10], P = 0.007). Pooled data regression analysis showed that increasing ropivacaine concentration increased grip weakness but not block duration.
Ropivacaine interscalene block requires a threshold volume and concentration, with concentration primarily determining motor block. When combined with continuous blockade, suprathreshold ropivacaine doses do not significantly prolong primary block duration but may compromise patient satisfaction.
本三阶段研究旨在评估在全身麻醉下进行肩部手术后预防恢复室疼痛所需的肋间罗哌卡因容量和浓度。
阶段 1/2:根据前一位患者是否出现恢复室疼痛,采用 10%递增上下序贯法给予肋间导管罗哌卡因。阶段 1:罗哌卡因(0.5%体积)从 30 ml 变化。阶段 2:罗哌卡因(20 ml,来自阶段 1 的 ED(体积)95 估计值)浓度从 0.45%变化。阶段 3:受试者随机分为接受 30 ml 罗哌卡因,0.5%(“常规剂量”)或 20 ml 罗哌卡因,0.375%(来自阶段 1/2 的估计 ED(体积+浓度)95)。术后给予 0.2%罗哌卡因弹性输注(2 ml/h)。在恢复室测量握力,并在 24 小时测量首次疼痛时间。
阶段 1(n=34):罗哌卡因 0.5%ED(体积)50/ED(体积)95(95%CI)估计值分别为 2.7/20.5 ml(2.4-9.5/17.3-25.8)。阶段 2(n=29):罗哌卡因 20 ml ED(浓度)50/ED(浓度)95(95%CI)估计值分别为 0.15/0.34%(0.13-0.30/0.29-0.43)。第 1/2 阶段的 ED(剂量)50 相似(13.5 与 30 mg),但第 1 阶段的 ED(剂量)95 较高(102.5 与 68 mg)。第 3 阶段(n=40):新/低剂量的满意度(0-10)略高(中位数[四分位间距]为 10[10-10]与 9[8-10],P=0.007)。汇总数据回归分析显示,罗哌卡因浓度的增加会导致握力减弱,但不会延长阻滞时间。
肋间罗哌卡因阻滞需要一个阈值的体积和浓度,浓度主要决定运动阻滞。当与连续阻滞结合时,超阈值罗哌卡因剂量不会显著延长主要阻滞时间,但可能会影响患者满意度。